Here we studied whether kinase activity was underlying Brk’s growth-promoting effect in human tumour xenografts and breast cancer cell sensitivity to chemotherapeutic agents in vitro and examined whether alternative splicing of Brk had any impact on patient outcomes. The gene discussed is PTK6; the disease is neoplasm.